Home World News Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive,... World News Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 552 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Strong Independent Association of TILs with OS for Patients with ERBB2-positive... February 26, 2025 Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... April 30, 2024 Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... May 19, 2021 Load more HOT NEWS SABCS 2021: New Research and Updates in Breast Cancer Treatment and... Mental Health Awareness for Health Care Providers Selumetinib Approved by FDA to Treat Children with NF1 Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says
